Advanced Hepatocellular Carcinoma clinical trials

Explore recruiting advanced hepatocellular carcinoma clinical trials.

Recruiting advanced hepatocellular carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Hepatocellular Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

Romania, Poland, Spain, Czechia, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare toripalimab (JS001) combined with lenvatinib versus placebo combined with lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)

Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)

Italy, Germany, France, Poland, Spain, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (SIERRA)

Germany, Spain, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Advanced Hepatocellular Carcinoma trials by city

Advanced Hepatocellular Carcinoma clinical trials

Recruiting advanced hepatocellular carcinoma studies right now

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

A Study of MGC026 in Participants With Advanced Solid Tumors

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Also recruiting in Europe

A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2

A phase I study evaluating safety and efficacy of Hepatic Intra- Arterial administration of ipilimumab in combination with Intra- venous nivolumab for advanced Hepatocellular carcinoma (HIPANIV)

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

A prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to compare toripalimab (JS001) combined with lenvatinib versus placebo combined with lenvatinib as the 1st-line therapy for advanced hepatocellular carcinoma (HCC)

A Phase III, Randomised, Open-Label, Sponsor-Blinded, Multicenter Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (ARTEMIDE-HCC01)

A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (SIERRA)

Advanced Hepatocellular Carcinoma trials by city

Other conditions